StockNews.AI
BCDA
StockNews.AI
85 days

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

1. BioCardia CEO to discuss pipeline developments on May 21, 2025. 2. Focus will be on CardiAMP therapy for ischemic heart failure. 3. The event is hosted by Alliance Global Partners. 4. BioCardia specializes in cardiovascular and pulmonary disease treatments. 5. Three cardiac clinical stage product candidates are in development.

3m saved
Insight
Article

FAQ

Why Bullish?

Dr. Altman's presentation could attract investor interest, similar to past successful introductions.

How important is it?

The showcase highlights BioCardia's advancements, potentially increasing investor confidence.

Why Short Term?

Immediate interest possible from upcoming showcase; investors may react quickly.

Related Companies

CARDMDCO
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025. Dr. Altman will share recent business developments on the Company’s therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure. Fireside Chat Details: Date: Wednesday, May 21, 2025 Time: 03:40 p.m. EDT Speaker: Peter Altman Ph.D., CEO Moderator: Jim Molloy, AGP Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals Webcast: https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw About BioCardia®BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.

Related News